Liz Lightstone, MBBS, PhD, FRCP, professor of renal medicine for the faculty of medicine, Imperial College London, discussed recently approved therapeutic options for patients with lupus nephritis and what unmet needs persist in the management of the disease.
Poor response rates and overuse of steroids are 2 issues facing the therapeutic management of lupus nephritis, with improved combination therapies warranted to better meet the needs of patients with the disease, said Liz Lightstone, MBBS, PhD, FRCP, professor of renal medicine for the faculty of medicine, Imperial College London.
Lightstone spoke during a session at the American Society of Nephrology Kidney Week 2022 meeting, titled, “Treatment of Lupus Nephritis: Beyond the Usual Suspects."
Transcript
Can you speak on the emerging treatment options for patients with lupus nephritis and any potential unmet needs addressed by these therapies?
There's really been a surge in approved drugs. We have 3 new approved drugs: belimumab, voclosporin, anifrolumab not so much for lupus, [inaudible] for nephritis. And there's other drugs coming in the pipeline that look optimistic, like obinutuzumab.
Where are the unmet needs with them? Well, they all improve outcomes compared to standard of care when they’re added on. So, that's a bonus. But if you look at the absolute rates of response, there's still only a percentage responding. At 2 years in the belimumab study, 30% had a complete response.
And if we think that you need a good response, you probably don't need a stringent response or a complete response; there's data to support that. But if you think about even a response where your proteinuria is down to 0.7, it's still only a proportion of patients achieving that. So, the unmet need is the failure to achieve that in a large group of patients. And if you're not achieving that, are those patients who are losing nephrons going to end up with worse renal function over time?
So, I think we still need better combinations. We still use far too much steroids. I would like treatments that get rid of steroids rather than just a rapid taper. We've improved; the voclosporin study used a really good rapid taper. But I think the main unmet needs are the problems of not responding, though I think there's a difference between trials and the real world, because we will have better responses in the real world.
The problem of side effects of treatment. And these are all add ons, so patients end up on a lot of stuff and they don't like being on a lot of stuff. Finding the optimal combination of therapy for the right patient at the right time, I think is what we need to do and we're not there yet.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More